What Researchers Did
This review article examined the potential beneficial effects, underlying mechanisms, and optimal strategies for co-administering hyperbaric oxygen therapy (HBOT) with recombinant tissue-type plasminogen activator (r-tPA) for acute ischaemic stroke.
What They Found
The review highlighted that hyperbaric oxygen therapy (HBOT) is considered potentially neuroprotective and its co-administration with recombinant tissue-type plasminogen activator (r-tPA) has shown promise for acute ischaemic stroke. Existing evidence, particularly from myocardial infarction studies, indicates that combining r-tPA and HBOT has been proven effective, safe, and feasible.
Canadian Relevance
This review article does not have a direct Canadian connection.
Study Limitations
As a review article, this study synthesizes existing literature but highlights the need for further primary research to confirm the optimal mechanisms and clinical efficacy of this co-administration strategy.